Abstract
A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment
| Original language | English (US) |
|---|---|
| Pages (from-to) | 107-115 |
| Number of pages | 9 |
| Journal | Ophthalmic Research |
| Volume | 52 |
| Issue number | 3 |
| DOIs | |
| State | Published - Nov 19 2014 |
Keywords
- Age-related macular degeneration
- Drugs
- Drusen
- Geographic atrophy
- Neurotrophic factors
- Oxidative damage
- Pathway
- Stem cells
- Treatment
- Visual cycle
ASJC Scopus subject areas
- Ophthalmology
- Sensory Systems
- Cellular and Molecular Neuroscience
Fingerprint Dive into the research topics of 'Treatment of dry age-related macular degeneration'. Together they form a unique fingerprint.
Cite this
Querques, G., Rosenfeld, P. J., Cavallero, E., Borrelli, E., Corvi, F., Querques, L., Bandello, F. M., & Zarbin, M. A. (2014). Treatment of dry age-related macular degeneration. Ophthalmic Research, 52(3), 107-115. https://doi.org/10.1159/000363187